Back to Main

Faculty Detail    
Name PETER G PAPPAS
 
Campus Address THT 229 Zip 0006
Phone  (20-5) -951
E-mail  pappas@uab.edu
Other websites
     


Faculty Appointment(s)
Appointment Type Department Division Rank
Primary  Medicine  Med - Infectious Diseases Professor
Center  Center for AIDS Research  Center for AIDS Research Professor
Center  General Clinical Research Center  Center for Outcomes & Effectiveness Res & Educ Professor
Center  Comprehensive Cancer Center  Comprehensive Cancer Center Professor
Center  General Clinical Research Center  Ctr for Clinical & Translational Sci Professor



Research/Clinical Interest
Title
Description
Dr. Peter G. Pappas is Professor of Medicine and has been an active UAB site investigator with the NIAID sponsored Mycoses Study Group over the last thirteen years, having served as Protocol Chair or Co-Chair for four MSG studies, and has been one of the highest investigator enrollees of patients into MSG trials during that period of time. He is presently serving as a member of the Steering Committee of the Mycoses Study Group and is in charge of the Orphan Studies Fund as part of the most recent BAMSG contract. Dr. Pappas is also Co-Director of the Mycology Reference Laboratory at UAB, and as such, has mentored John Baddley, M.D.; a young faculty member with a special interest in the epidemiology of fungal diseases and antifungal susceptibility testing. Dr. Pappas recently successfully competed for a CDC grant entitled “Prospective Surveillance of Invasive Fungal Infections in Bone Marrow and Solid Organ Transplant Recipients” for 2000-2003. This major epidemiologic investigation is being coordinated by Dr. Pappas and his staff at UAB and involves twenty-four different sites from across the United States, and represents the largest study of its kind. Dr. Pappas’ specific interests include the epidemiology of invasive fungal infections and investigation of newer antifungal agents for the treatment and prevention of invasive fungal infections, including the use of adjunctive agents such as IFN gamma, which can be used in conjunction with conventional therapy. He has published clinical data concerning a wide variety of invasive mycoses including cryptococcosis, blastomycosis, sporotrichosis, invasive candidiasis, and invasive aspergillosis. His current active projects include a phase-I study to determine the safety and pharmacokinetics of a murine derived anticryptococcal monoclonal antibody administered to patients with a previous history of CNS cryptococcosis, and a Phase III trial to evaluate IFN gamma in conjunction with conventional antifungal therapy for HIV-infected patients with acute cryptococcal meningitis.

Selected Publications 
Publication PUBMEDID
Rex JH, Walsh TJ, Sobel JD, Filler SG, Pappas PG, Dismukes WE, Edwards JE. Practice guidelines for the treatment of candidiasis. Clin Infect Dis 2000; 30:662-678.   
Chapman SW, Bradsher RW, Campbell DG, Pappas PG, Kauffman CA. Practice guidelines for the management of patients with blastomycosis. Clin Infect Dis 2000; 30:679-683.   
Saag MS, Graybill JR, Larsen RA, Pappas PG, Perfect JR, Powderly WG, Sobel JD, Dismukes WE for the Mycoses Study Group Cryptococcal Subproject. Practice guidelines for the management of cryptococcal disease. Clin Infect Dis 2000; 30:710-718.   
Baddley JW, Pappas PG. Cryptococcosis. Curr Opin Inf Dis 2000; 2:525-533.   
Baddley JW, Smith AM, Moser SA, Pappas PG. Trends in frequency and susceptibilities of Candida glabrata bloodstream isolates at a University Hospital. Diag Micro Infect Dis 2001;39:199-201.   
Baddley JW, Stroud TP, Salzman D, and Pappas PG. Invasive mould infections in allogeneic bone marrow transplant recipients. Clin Infect Dis 2001; 32:1319-1324.   
Pappas PG, Perfect JR, Cloud GA, Larsen RA, Pankey GA, Lancaster DJ, Henderson H, Kauffman CA, Haas DW, Saccente M, Hamill RJ, Holloway MS, Warren RM, Dismukes WE. Cryptococcosis in HIV-negative patients in the era of effective azole therapy. Clin Infect Dis 2001; 33:690-699.   
Pappas PG. Therapy of cryptococcal meningitis in non-HIV-infected patients. Current Infectious Disease Reports 2001;3:365-370.   
Donowitz GR, Maki DG, Pappas PG, Rolston K. Infection in the neutropenic patient-new views of an old problem. Hematology 2001;93-119.   
Walsh TJ, Goodman JL, Pappas PG, Bekersky I, Buell DN, Roden M, Barrett J, Anaissie EJ. Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study. Antimicrob Agents Chemother 2001;45:3487-3496.